2023
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
Nassar A, Adib E, Feng J, Aredo J, Parikh K, Harris J, Velazquez Manana A, Ragavan M, Lin J, Piotrowska Z, Fitzgerald B, Grohé C, Sankar K, Neal J, Wakelee H, Shepherd F, Herbst R, Naqash A, Goldberg S, Kim S. EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC). Journal Of Clinical Oncology 2023, 41: 8567-8567. DOI: 10.1200/jco.2023.41.16_suppl.8567.Peer-Reviewed Original ResearchEGFR tyrosine kinase inhibitorsDisease-free survivalTyrosine kinase inhibitorsTreatment-related adverse eventsConcurrent chemoradiationOverall survivalStage IIILonger disease-free survivalMulti-institutional retrospective analysisDefinitive radiation therapyPD-L1 expressionPD-L1 statusDefinitive concurrent chemoradiationEGFR-TKI therapyPlatinum-based chemotherapyCell lung cancerEGFR-mutant NSCLCGy of radiationAdjuvant osimertinibCTCAE 5.0PACIFIC trialAdvanced NSCLCConcurrent chemotherapyBaseline characteristicsMedian duration
2017
Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial.
Thress K, Markovets A, Barrett J, Chmielecki J, Goldberg S, Shepherd F, Vowler S, Oxnard G. Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial. Journal Of Clinical Oncology 2017, 35: 9018-9018. DOI: 10.1200/jco.2017.35.15_suppl.9018.Peer-Reviewed Original ResearchMedian progression-free survivalPlasma EGFR mutationsDetectable EGFR mutationsEGFR mutationsClinical outcomesOverall median progression-free survivalResponse ratePlasma samplesDurable response rateHeterogeneous resistance mechanismsObjective response ratePositive advanced NSCLCProgression-free survivalEGFR-TKI therapyPredictors of outcomeTyrosine kinase inhibitorsBaseline genotypingEvaluable baselinePositive genotypingAdvanced NSCLCPositive NSCLCCombination therapyEGFR-TKIsOsimertinib therapyComplete clearance